EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Emerging Role of Lenvatinib in Treating Platinum-Refractory Head and Neck Cancer in Resource-Limited Settings

Avinash Khadela, Kashvy R. Morakhia, Nishra H. Shah, Vibha G. Kanjani, Rushabh Kothari, Manthan Merja

Indian Journal of Medical and Paediatric Oncology · 2025-10 · 46 (05) · 453-460

DOI: 10.1055/s-0045-1809377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, online erschienen am 27.05.2025. Verfasst von Avinash Khadela und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenvatinib, an oral multiple tyrosine kinase inhibitor, is currently being explored in the area of head and neck squamous cell carcinoma (HNSCC). Two-thirds of total patients are presented in the advanced stage leading to poor prognosis with conventional treatment. The addition of immunotherapy is the standard approach to it. However, in developing nations and resource-limited setups, affordability is the major concern. To encounter this, lenvatinib has become a novel cost-effective treatment for HNSCC. Lenvatinib targets a varied range of receptors including vascular endothelial growth factor receptor, platelet-derived growth factor receptor α, fibroblast growth factor receptor, KIT (stem cell factor receptor), and rearranged during transfection, all of which are involved in the pathogenesis of HNSCC leading to the establishment of its role in HNSCC. It inhibits angiogenesis in endothelial cells and proliferation in tumor cells. Instances of resistance were observed in monoreceptor targeting agents, which are also overcome by lenvatinib, leading to potent antitumor activity. Clinical studies are being conducted to establish the role of lenvatinib as a third-line therapy in HNSCC. In this review, we discuss the role of lenvatinib in resource-limited, platinum-refractory, and recurrent/metastatic HNSCC.

Zitieren

APA

Khadela, A., Morakhia, K. R., Shah, N. H., Kanjani, V. G., Kothari, R., & Merja, M. (2025). Emerging Role of Lenvatinib in Treating Platinum-Refractory Head and Neck Cancer in Resource-Limited Settings. Indian Journal of Medical and Paediatric Oncology, 46(05), 453-460. https://doi.org/10.1055/s-0045-1809377

Vancouver

Khadela A, Morakhia KR, Shah NH, Kanjani VG, Kothari R, Merja M. Emerging Role of Lenvatinib in Treating Platinum-Refractory Head and Neck Cancer in Resource-Limited Settings. Indian Journal of Medical and Paediatric Oncology. 2025;46(05):453-460. doi:10.1055/s-0045-1809377

BibTeX
@article{Khadela2025,
  author = {Khadela, Avinash and Morakhia, Kashvy R. and Shah, Nishra H. and Kanjani, Vibha G. and Kothari, Rushabh and Merja, Manthan},
  title = {Emerging Role of Lenvatinib in Treating Platinum-Refractory Head and Neck Cancer in Resource-Limited Settings},
  journal = {Indian Journal of Medical and Paediatric Oncology},
  year = {2025},
  volume = {46},
  number = {05},
  pages = {453--460},
  doi = {10.1055/s-0045-1809377}
}
Kostenlos starten →